Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/195244
Authors: 
Lichtenberg, Frank R.
Year of Publication: 
2017
Citation: 
[Journal:] Latin American Economic Review [ISSN:] 2196-436X [Volume:] 26 [Year:] 2017 [Issue:] 8 [Pages:] 1-22
Abstract: 
I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003-2013, by investigating whether there were larger declines in the age-standardized mortality rate of cancer sites (breast, lung, colon, etc.) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate. The estimates indicate that new drugs launched during 1991-2001 reduced the age-standardized cancer mortality rate by 16%, i.e., at an average annual rate of about 1.6%. I estimate that 105,661 life-years before age 70 were gained in 2013 due to cancer drugs launched during 1991-2001, and that the cost per life-year gained was in the neighborhood of $2146. By the standards of the World Health Organization, new cancer drugs have been very cost-effective in Mexico. The contribution of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger. Only half as many new cancer drugs were launched in Mexico during 2010-2014 as were launched in the US. In addition, when new drugs are launched in Mexico, their diffusion tends to be quite slow.
Subjects: 
Pharmaceutical
Innovation
Mortality
Longevity
Cancer
Mexico
Cost-effectiveness
JEL: 
I1
J11
L65
O33
Persistent Identifier of the first edition: 
Creative Commons License: 
https://creativecommons.org/licenses/by/4.0/
Document Type: 
Article
Social Media Mentions:

Files in This Item:
File
Size
639.05 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.